A Phase 3 interventional study of Tocilizumab and DMARDs in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 49 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-11.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 28th largest by enrollment, is one of 9 that started in 2013, is one of 65 in phase 3, and was the 75th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 9 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 51st largest by enrollment of the 141 interventional ones that give a count, is one of 14 that started in 2013, is one of 85 in phase 3, and was the 171st registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, single arm, Phase 3b study will evaluate the efficacy of tocilizumab (RoActemra), administered as monotherapy or in combination with methotrexate and/or other DMARDs, in participants with moderate to severe active RA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tocilizumab at a fixed dose of 162 milligrams (mg) will be administered as subcutaneous (SC) injection alone or along with methotrexate and/or other non-biological DMARDs irrespective of body weight, once every week for a total of 52 weeks. After 52-weeks of treatment, at the discretion of the treating physician, participants can continue the study treatment with SC tocilizumab until it becomes commercially available in Italy.
Drug: Tocilizumab · Drug: DMARDs
Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.
Also known as: RoActemra
Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
The CDAI is a numerical sum of 4 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) based on a 28-joint assessment, patient's global assessment of disease activity (PtGDA) and physician global assessment of disease activity (PGDA) assessed on 0-10 centimeters (cm) visual analogue scale (VAS). Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score less than or equal to (\</=) 2.8 indicates disease remission, greater than (\>) 2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
Time frame: Baseline, Week 24
Change From Baseline in CDAI at Week 20
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
Time frame: Baseline, Week 20
Change From Baseline in CDAI at Week 16
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
Time frame: Baseline, Week 16
Change From Baseline in CDAI at Week 12
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
Time frame: Baseline, Week 12
Change From Baseline in CDAI at Week 8
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
Time frame: Baseline, Week 8
Change From Baseline in CDAI at Week 4
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
Time frame: Baseline, Week 4
Change From Baseline in CDAI at Week 2
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
Time frame: Baseline, Week 2
Number of Participants Achieving Clinical Remission According to CDAI up to Week 52
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 during any two consecutive visits, not including the baseline visit indicates disease remission.
Time frame: Baseline up to Week 52 (Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 38, and 52)
Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (DAS28-ESR) at Weeks 2, 24, and 52
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hour) and PtGDA assessed on 0-10 cm VAS. Higher scores indicate greater affectation due to disease activity. DAS28-ESR total score= 0-9.4. DAS28-ESR \</=3.2 indicates low disease activity, DAS28-ESR \>3.2 to 5.1 indicates moderate to high disease activity, and DAS28-ESR \</=3.2 indicates remission.
Time frame: Baseline, Weeks 2, 24, and 52
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 24, and 52
SDAI is a numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and C-reactive protein (CRP) in milligrams per deciliter (mg/dL). Higher scores indicate greater affectation due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity, \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity.
Time frame: Baseline, Weeks 2, 24, and 52
Percentage of Participants With an American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) Response
The ACR 20, 50, and 70 responses: greater than or equal to (\>/=) 20 percent (%), 50%, and 70% improvement in TJC and SJC (28 assessed joints), and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP or ESR at each visit.
Time frame: Weeks 2, 24, and 52
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 \</=3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1; non-responders: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1.
Time frame: Baseline, Weeks 2, 24, and 52
Change From Baseline in Total TJC at Weeks 2, 24, and 52
TJC was defined as the total number of painful joints based on 68-joint assessment (TJC-68) and 28-joint assessment (TJC-28).
Time frame: Baseline, Weeks 2, 24, and 52
Change From Baseline in Total SJC at Weeks 2, 24, and 52
SJC was defined as the total number of swollen joints based on 66-joint assessment (SJC-66) and 28-joint assessment (SJC-28).
Time frame: Baseline, Weeks 2, 24, and 52
Association Between Disease Activity Parameters: DAS28-ESR and CDAI, Assessed Using Correlation Coefficient
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. Higher scores indicate greater affectation due to disease activity. The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. Higher scores represent greater affectation due to disease activity. Correlation coefficient for relationship between DAS28-ESR and CDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.
Time frame: Weeks 2, 24, 52
Association Between Disease Activity Parameters: DAS28-ESR and SDAI, Assessed Using Correlation Coefficient
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. Higher scores indicate greater affectation due to disease activity. SDAI is a numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. Higher scores indicate greater affectation due to disease activity. Correlation coefficient for relationship between DAS28-ESR and SDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.
Time frame: Weeks 2, 24, 52
Association Between Disease Activity Parameters: CDAI and SDAI, Assessed Using Correlation Coefficient
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. Higher scores represent greater affectation due to disease activity. SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. Higher scores indicate greater affectation due to disease activity. Correlation coefficient for relationship between CDAI and SDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.
Time frame: Weeks 2, 24, 52
Association Between Disease Activity Parameter (DAS28-ESR) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between DAS28-ESR and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
Time frame: Weeks 2, 24, 52
Association Between Disease Activity Parameter (DAS28-ESR) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between DAS28-ESR and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
Time frame: Weeks 2, 24, 52
Association Between Disease Activity Parameter (CDAI) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between CDAI and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
Time frame: Weeks 2, 24, 52
Association Between Disease Activity Parameter (CDAI) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between CDAI and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
Time frame: Weeks 2, 24, 52
Association Between Disease Activity Parameter (SDAI) and Treatment Response Parameters (ACR20, ACR50, and ACR70), Assessed Using Regression Coefficient
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between SDAI and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
Time frame: Weeks 2, 24, 52
Association Between Disease Activity Parameter (SDAI) and Treatment Response Parameter (EULAR), Assessed Using Regression Coefficient
The SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between SDAI and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
Time frame: Weeks 2, 24, 52
Percentage of DMARDs Dose Reductions and/or Discontinuation Events by Reasons
Percentage of DMARDs dose reduction and/or discontinuation (Red/Dis) events is reported by different reasons.
Time frame: Baseline up to Week 52
Percentage of Non-DMARDs Dose Reductions and/or Discontinuation Events by Reasons
Percentage of Non-DMARDs dose reduction and/or discontinuation (Red/Dis) events is reported by different reasons.
Time frame: Baseline up to Week 52
Change From Baseline in PtGDA VAS Score at Weeks 2, 24, and 52
Participants answered the following question: "Considering all the ways your arthritis affects you, how are you feeling today." Participants responded by using a 0 - 100 millimeter (mm) VAS, where 0 mm = very well and 100 mm = very poorly.
Time frame: Baseline, Weeks 2, 24, and 52
Change From Baseline in PGDA VAS Score at Weeks 2, 24, and 52
The physician assessed participant's current disease activity on a 0-100 mm VAS, where 0 mm = no disease activity and 100 mm = maximum disease activity.
Time frame: Baseline, Weeks 2, 24, and 52
Participant Pain VAS Score at Weeks 2, 24, and 52
Participants assessed their pain using a 0-100 mm VAS. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain.
Time frame: Weeks 2, 24, and 52
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Weeks 2, 24, and 52
HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline, Weeks 2, 24, and 52
Missed Working Days Assessed Using Short Form-Health and Labor Questionnaire (SF-HLQ) Score at Weeks 24 and 52
The SF-HLQ assessed productivity losses related to health problems in individuals with paid or unpaid work and consisted of three modules (absenteeism from paid work, production losses without absenteeism from paid work and hindrance in the performance of paid and unpaid work). Any missed working days or number of worked days with reduced efficiency during the last month were reported.
Time frame: Weeks 24 and 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Total Score at Weeks 2, 24, and 52
FACIT total score is sum of Functional Assessment of Cancer Therapy-General (FACT-G) score and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F; additional concerns) score. FACT-G is a core questionnaire that evaluates quality of life (QoL) in cancer population. FACT-G consists of 27 questions grouped in 4 domains of general health-related QoL: physical well-being, social/family well-being, emotional well-being, and functional well-being; each item ranges from 0 (not at all) to 4 (very much). FACT-G score ranges between 0-108. FACIT-F is a 13-item questionnaire that evaluates self-reported fatigue and its impact upon daily activities. Each item ranges from 0 (Not at all) to 4 (Very much). The sum of all responses result in the FACIT total score with a total possible range of 0 (better score) to 160 (worse score). Negative change from baseline represents a better QoL.
Time frame: Baseline, Weeks 2, 24, and 52
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) at Weeks 24 and 52
PSQI is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction). A participant indicates how frequently each item was experienced on a scale from 0 to 3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality. A score of \>/=5 indicates poor sleepers.
Time frame: Baseline, Weeks 24 and 52
Treatment Compliance, as Assessed Using Participant Diary Cards and Return Records
Treatment Compliance was calculated as (total actual doses taken for the period) / (total planned or prescribed dose for the period) x 100.
Time frame: Weeks 24 and 52
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) of Special Interest
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs are AEs occurring between the first dose of study drug and up to 28 days after the last dose that were absent before treatment or that worsened relative to pre-treatment state. Following AEs were considered as AEs of special interest: anaphylactic reaction, hypersensitivity, stress cardiomyopathy, Gilbert's syndrome, gastrointestinal perforation, injection site erythema, injection site hypersensitivity, injection site irritation, injection site pruritus, arthritis bacterial, cellulitis, klebsiella infection, oral candidiasis, pneumonia, skin infection, vulvovaginal candidiasis, alanine aminotransferase increased, hepatic enzyme increased, brain neoplasm malignant, and urticaria.
Time frame: Baseline up to 95 weeks
Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to Tocilizumab
Percentage of participants with positive results for ATA against tocilizumab at different time points is reported.
Time frame: Baseline, Weeks 12, 24, 38, 52, at 8 weeks after last dose (up to Week 60), at early withdrawal (up to Week 52), at Follow-up Visits 1 (Week 64), 2 (Week 76), and 3 (Week 88)
Mean Tocilizumab Concentration
Time frame: Baseline, Weeks 12, 24, 38, 52, at early withdrawal (up to Week 52), at Follow-up Visit 2 (Week 76)
Mean Soluble Interleukin-6 Receptor (sIL-6R) Concentration
Time frame: Baseline, Weeks 12, 24, 38, 52, at early withdrawal (up to Week 52), at Follow-up Visit 2 (Week 76)
| Milestone | Tocilizumab |
|---|---|
| Started | 227 |
| Completed | 194 |
| Not completed | 33 |
| Withdrew: Adverse event | 11 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Physician decision | 2 |
| Withdrew: Withdrawal by subject | 15 |
| Withdrew: Death | 1 |
| Withdrew: Other | 1 |
| Withdrew: Other | 1 |
The CDAI is a numerical sum of 4 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) based on a 28-joint assessment, patient's global assessment of disease activity (PtGDA) and physician global assessment of disease activity (PGDA) assessed on 0-10 centimeters (cm) visual analogue scale (VAS). Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score less than or equal to (\</=) 2.8 indicates disease remission, greater than (\>) 2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24 | -21.6 ± 13.25 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Change From Baseline in CDAI at Week 20 | -21.3 ± 12.87 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Change From Baseline in CDAI at Week 16 | -20.2 ± 12.53 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Change From Baseline in CDAI at Week 12 | -19.1 ± 12.46 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Change From Baseline in CDAI at Week 8 | -17.7 ± 12.07 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Change From Baseline in CDAI at Week 4 | -14.0 ± 11.57 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Change From Baseline in CDAI at Week 2 | -9.1 ± 9.71 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. Higher scores represent greater affectation due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 during any two consecutive visits, not including the baseline visit indicates disease remission.
| participants | Tocilizumab |
|---|---|
| Number of Participants Achieving Clinical Remission According to CDAI up to Week 52 | 10 |
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hour) and PtGDA assessed on 0-10 cm VAS. Higher scores indicate greater affectation due to disease activity. DAS28-ESR total score= 0-9.4. DAS28-ESR \</=3.2 indicates low disease activity, DAS28-ESR \>3.2 to 5.1 indicates moderate to high disease activity, and DAS28-ESR \</=3.2 indicates remission.
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=216) | 5.81 ± 1.080 |
| Change at Week 2 (n=208) | -1.5 ± 1.04 |
| Change at Week 24 (n=174) | -3.2 ± 1.47 |
| Change at Week 52 (n=31) | -3.6 ± 1.18 |
SDAI is a numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and C-reactive protein (CRP) in milligrams per deciliter (mg/dL). Higher scores indicate greater affectation due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity, \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=215) | 48.70 ± 45.790 |
| Change at Week 2 (n=203) | -26.5 ± 44.04 |
| Change at Week 24 (n=176) | -38.9 ± 48.75 |
| Change at Week 52 (n=29) | -39.3 ± 26.82 |
The ACR 20, 50, and 70 responses: greater than or equal to (\>/=) 20 percent (%), 50%, and 70% improvement in TJC and SJC (28 assessed joints), and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP or ESR at each visit.
| percentage of participants | Tocilizumab |
|---|---|
| Week 2: ACR 20 (n=222) | 18.5 |
| Week 2: ACR 50 (n=222) | 6.3 |
| Week 2: ACR 70 (n=222) | 11.7 |
| Week 24: ACR 20 (n=192) | 8.3 |
| Week 24: ACR 50 (n=192) | 4.7 |
| Week 24: ACR 70 (n=192) | 65.6 |
| Week 52: ACR 20 (n=70) | 0.0 |
| Week 52: ACR 50 (n=70) | 0.0 |
| Week 52: ACR 70 (n=70) | 40.0 |
The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline \>1.2 with DAS28 \</=3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1; non-responders: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1.
| percentage of participants | Tocilizumab |
|---|---|
| Week 2: No Response (n=222) | 32.4 |
| Week 2: Moderate Response (n=222) | 50.5 |
| Week 2: Good Response (n=222) | 17.1 |
| Week 24: No Response (n=192) | 13.5 |
| Week 24: Moderate Response (n=192) | 25.0 |
| Week 24: Good Response (n=192) | 61.5 |
| Week 52: No Response (n=70) | 55.7 |
| Week 52: Moderate Response (n=70) | 8.6 |
| Week 52: Good Response (n=70) | 35.7 |
TJC was defined as the total number of painful joints based on 68-joint assessment (TJC-68) and 28-joint assessment (TJC-28).
| tender joints | Tocilizumab |
|---|---|
| TJC-68, Baseline (n=223) | 16.91 ± 10.860 |
| TJC-68, Change at Week 2 (n=218) | -5.4 ± 8.38 |
| TJC-68, Change at Week 24 (n=188) | -12.9 ± 11.18 |
| TJC-68, Change at Week 52 (n=69) | -16.5 ± 10.35 |
| TJC-28, Baseline (n=224) | 11.32 ± 6.241 |
| TJC-28, Change at Week 2 (n=219) | -3.7 ± 5.40 |
| TJC-28, Change at Week 24 (n=189) | -8.6 ± 6.62 |
| TJC-28, Change at Week 52 (n=70) | -11.0 ± 6.14 |
SJC was defined as the total number of swollen joints based on 66-joint assessment (SJC-66) and 28-joint assessment (SJC-28).
| swollen joints | Tocilizumab |
|---|---|
| SJC-66, Baseline (n=223) | 9.53 ± 6.713 |
| SJC-66, Change at Week 2 (n=218) | -3.7 ± 4.94 |
| SJC-66, Change at Week 24 (n=188) | -8.3 ± 6.73 |
| SJC-66, Change at Week 52 (n=69) | -9.1 ± 6.66 |
| SJC-28, Baseline (n=224) | 7.90 ± 5.203 |
| SJC-28, Change at Week 2 (n=219) | -2.9 ± 3.91 |
| SJC-28, Change at Week 24 (n=189) | -6.7 ± 5.17 |
| SJC-28, Change at Week 52 (n=70) | -7.6 ± 4.63 |
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. Higher scores indicate greater affectation due to disease activity. The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. Higher scores represent greater affectation due to disease activity. Correlation coefficient for relationship between DAS28-ESR and CDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.
| correlation coefficient | Tocilizumab |
|---|---|
| Week 2 (n=213) | 0.86514 |
| Week 24 (n=182) | 0.86944 |
| Week 52 (n=32) | 0.87301 |
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. Higher scores indicate greater affectation due to disease activity. SDAI is a numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. Higher scores indicate greater affectation due to disease activity. Correlation coefficient for relationship between DAS28-ESR and SDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.
| correlation coefficient | Tocilizumab |
|---|---|
| Week 2 (n=213) | 0.88118 |
| Week 24 (n=182) | 0.87060 |
| Week 52 (n=31) | 0.81995 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. Higher scores represent greater affectation due to disease activity. SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. Higher scores indicate greater affectation due to disease activity. Correlation coefficient for relationship between CDAI and SDAI at different time points is reported. Correlation coefficient value range= -1 to 1. Higher positive value indicates greater positive relationship and higher negative value indicates greater negative relationship.
| correlation coefficient | Tocilizumab |
|---|---|
| Week 2 (n=213) | 0.98602 |
| Week 24 (n=185) | 0.97515 |
| Week 52 (n=31) | 0.97389 |
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between DAS28-ESR and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
| regression coefficient | Tocilizumab |
|---|---|
| Week 2: DAS28-ESR and ACR20 (n=213) | -1.02676 |
| Week 2: DAS28-ESR and ACR50 (n=213) | -1.31737 |
| Week 2: DAS28-ESR and ACR70 (n=213) | -1.50400 |
| Week 24: DAS28-ESR and ACR20 (n=182) | -1.71191 |
| Week 24: DAS28-ESR and ACR50 (n=182) | -1.54281 |
| Week 24: DAS28-ESR and ACR70 (n=182) | -1.43977 |
| Week 52: DAS28-ESR and ACR20 (n=32) | -2.05036 |
| Week 52: DAS28-ESR and ACR50 (n=32) | -2.05036 |
| Week 52: DAS28-ESR and ACR70 (n=32) | -2.05036 |
DAS28-ESR is calculated from the TJC and SJC based on a 28-joint assessment, the ESR in mm/hour and PtGDA. DAS28-ESR total score= 0-9.4. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between DAS28-ESR and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
| regression coefficient | Tocilizumab |
|---|---|
| Week 2: DAS28-ESR and EULAR (n=213) | -1.62883 |
| Week 24: DAS28-ESR and EULAR (n=182) | -1.36226 |
| Week 52: DAS28-ESR and EULAR (n=32) | -1.47781 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between CDAI and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
| regression coefficient | Tocilizumab |
|---|---|
| Week 2: CDAI and ACR20 (n=220) | -9.65473 |
| Week 2: CDAI and ACR50 (n=220) | -10.67389 |
| Week 2: CDAI and ACR70 (n=220) | -13.38810 |
| Week 24: CDAI and ACR20 (n=186) | -13.18433 |
| Week 24: CDAI and ACR50 (n=186) | -11.95933 |
| Week 24: CDAI and ACR70 (n=186) | -11.18299 |
| Week 52: CDAI and ACR20 (n=32) | -18.94643 |
| Week 52: CDAI and ACR50 (n=32) | -18.94643 |
| Week 52: CDAI and ACR70 (n=32) | -18.94643 |
The CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS. CDAI total score = 0-76. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between CDAI and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
| regression coefficient | Tocilizumab |
|---|---|
| Week 2: CDAI and EULAR (n=220) | -10.97686 |
| Week 24: CDAI and EULAR (n=186) | -7.03184 |
| Week 52: CDAI and EULAR (n=32) | -9.46563 |
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. The ACR 20, 50, and 70 responses: \>/=20%, 50%, and 70% improvement in TJC and SJC, and 20%, 50%, 70% improvement in 3 of the following 5 criteria, respectively: 1) PGDA, 2) PtGDA, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit. Regression coefficients for relationship between SDAI and ACR responses (ACR20, ACR50, and ACR70) at different time points are reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
| regression coefficient | Tocilizumab |
|---|---|
| Week 2: SDAI and ACR20 (n=213) | -9.44923 |
| Week 2: SDAI and ACR50 (n=213) | -10.74230 |
| Week 2: SDAI and ACR70 (n=213) | -13.31421 |
| Week 24: SDAI and ACR20 (n=185) | -14.19790 |
| Week 24: SDAI and ACR50 (n=185) | -12.65454 |
| Week 24: SDAI and ACR70 (n=185) | -11.78067 |
| Week 52: SDAI and ACR20 (n=31) | -22.83519 |
| Week 52: SDAI and ACR50 (n=31) | -22.83519 |
| Week 52: SDAI and ACR70 (n=31) | -22.83519 |
The SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGDA and PGDA assessed on 0-10 cm VAS and CRP in mg/dL. SDAI total score= 0-86. EULAR response criteria (based on DAS28 score): Good responders (change from baseline \>1.2 with DAS28 \</=3.2); Moderate responders (change from baseline \>1.2 with DAS28 \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28 \</=5.1); Non-responders (change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28 \>5.1). Regression coefficient for relationship between SDAI and EULAR Good response at different time points is reported. Regression coefficient value range= not defined (any negative or positive value is possible). Higher positive value indicates greater extent of positive relationship and higher negative value indicates greater extent of negative relationship.
| regression coefficient | Tocilizumab |
|---|---|
| Week 2: SDAI and EULAR (n=213) | -11.73463 |
| Week 24: SDAI and EULAR (n=185) | -7.32435 |
| Week 52: SDAI and EULAR (n=31) | -9.64146 |
Percentage of DMARDs dose reduction and/or discontinuation (Red/Dis) events is reported by different reasons.
| percentage of events | Tocilizumab |
|---|---|
| Safety | 27.7 |
| Discomfort | 9.5 |
| Lack of Efficacy | 29.7 |
| Other Than Above | 31.1 |
| Unknown | 2.0 |
Percentage of Non-DMARDs dose reduction and/or discontinuation (Red/Dis) events is reported by different reasons.
| percentage of events | Tocilizumab |
|---|---|
| Safety | 9.5 |
| Discomfort | 1.3 |
| Lack of Efficacy | 8.8 |
| Other Than Above | 73.7 |
| Unknown | 6.8 |
Participants answered the following question: "Considering all the ways your arthritis affects you, how are you feeling today." Participants responded by using a 0 - 100 millimeter (mm) VAS, where 0 mm = very well and 100 mm = very poorly.
| mm | Tocilizumab |
|---|---|
| Baseline (n=226) | 61.31 ± 23.526 |
| Change at Week 2 (n=220) | -10.6 ± 20.99 |
| Change at Week 24 (n=186) | -28.4 ± 27.40 |
| Change at Week 52 (n=32) | -38.4 ± 27.65 |
The physician assessed participant's current disease activity on a 0-100 mm VAS, where 0 mm = no disease activity and 100 mm = maximum disease activity.
| mm | Tocilizumab |
|---|---|
| Baseline (n=226) | 57.36 ± 19.228 |
| Change at Week 2 (n=220) | -15.3 ± 17.49 |
| Change at Week 24 (n=186) | -38.0 ± 25.13 |
| Change at Week 52 (n=32) | -43.9 ± 17.13 |
Participants assessed their pain using a 0-100 mm VAS. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain.
| mm | Tocilizumab |
|---|---|
| Baseline (n=226) | 58.21 ± 23.622 |
| Change at Week 2 (n=220) | -11.4 ± 22.38 |
| Change at Week 24 (n=186) | -26.5 ± 27.31 |
| Change at Week 52 (n=32) | -36.0 ± 26.82 |
HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=223) | 1.04 ± 0.687 |
| Change at Week 2 (n=215) | -0.2 ± 0.44 |
| Change at Week 24 (n=183) | -0.4 ± 0.63 |
| Change at Week 52 (n=31) | -0.5 ± 0.69 |
The SF-HLQ assessed productivity losses related to health problems in individuals with paid or unpaid work and consisted of three modules (absenteeism from paid work, production losses without absenteeism from paid work and hindrance in the performance of paid and unpaid work). Any missed working days or number of worked days with reduced efficiency during the last month were reported.
| days | Tocilizumab |
|---|---|
| Week 24 (n=69) | 6.4 ± 45.09 |
| Week 52 (n=7) | 0.3 ± 0.76 |
FACIT total score is sum of Functional Assessment of Cancer Therapy-General (FACT-G) score and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F; additional concerns) score. FACT-G is a core questionnaire that evaluates quality of life (QoL) in cancer population. FACT-G consists of 27 questions grouped in 4 domains of general health-related QoL: physical well-being, social/family well-being, emotional well-being, and functional well-being; each item ranges from 0 (not at all) to 4 (very much). FACT-G score ranges between 0-108. FACIT-F is a 13-item questionnaire that evaluates self-reported fatigue and its impact upon daily activities. Each item ranges from 0 (Not at all) to 4 (Very much). The sum of all responses result in the FACIT total score with a total possible range of 0 (better score) to 160 (worse score). Negative change from baseline represents a better QoL.
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=207) | 72.41 ± 16.806 |
| Change at Week 2 (n=196) | -5.8 ± 14.10 |
| Change at Week 24 (n=165) | -11.1 ± 18.60 |
| Change at Week 52 (n=60) | -43.8 ± 34.87 |
PSQI is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction). A participant indicates how frequently each item was experienced on a scale from 0 to 3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality. A score of \>/=5 indicates poor sleepers.
| units on a scale | Tocilizumab |
|---|---|
| Baseline (n=103) | 11.00 ± 2.719 |
| Change at Week 24 (n=73) | -0.7 ± 2.39 |
| Change at Week 52 (n=16) | -0.9 ± 2.42 |
Treatment Compliance was calculated as (total actual doses taken for the period) / (total planned or prescribed dose for the period) x 100.
| percentage of planned dose | Tocilizumab |
|---|---|
| Week 24 (n=221) | 94.9 ± 10.20 |
| Week 52 (n=222) | 94.7 ± 10.12 |
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs are AEs occurring between the first dose of study drug and up to 28 days after the last dose that were absent before treatment or that worsened relative to pre-treatment state. Following AEs were considered as AEs of special interest: anaphylactic reaction, hypersensitivity, stress cardiomyopathy, Gilbert's syndrome, gastrointestinal perforation, injection site erythema, injection site hypersensitivity, injection site irritation, injection site pruritus, arthritis bacterial, cellulitis, klebsiella infection, oral candidiasis, pneumonia, skin infection, vulvovaginal candidiasis, alanine aminotransferase increased, hepatic enzyme increased, brain neoplasm malignant, and urticaria.
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) of Special Interest | 7.5 |
Percentage of participants with positive results for ATA against tocilizumab at different time points is reported.
| percentage of participants | Tocilizumab |
|---|---|
| Baseline (n=227) | 2.6 |
| Week 12 (n=6) | 100.0 |
| Week 24 (n=179) | 1.7 |
| Week 38 (n=6) | 33.3 |
| Week 52 (n=161) | 1.2 |
| 8 Weeks After Last Dose (up to Week 60) (n=41) | 2.4 |
| Early Withdrawal (up to Week 52) (n=31) | 6.5 |
| Follow-up Visit 1 (Week 64) (n=16) | 100.0 |
| Follow-up Visit 2 (Week 76) (n=11) | 100.0 |
| Follow-up Visit 3 (Week 88) (n=3) | 100.0 |
| micrograms per milliliter (mcg/mL) | Tocilizumab |
|---|---|
| Baseline (n=2) | 35.6 ± 48.89 |
| Week 12 (n=186) | 46.4 ± 23.01 |
| Week 24 (n=177) | 52.6 ± 28.21 |
| Week 38 (n=169) | 55.2 ± 30.55 |
| Week 52 (n=165) | 54.0 ± 29.00 |
| Early Withdrawal (up to Week 52) (n=19) | 24.8 ± 22.90 |
| Follow-up Visit 2 (Week 76) (n=17) | 49.2 ± 34.05 |
| nanograms per milliliter (ng/mL) | Tocilizumab |
|---|---|
| Baseline (n=213) | 43.6 ± 49.30 |
| Week 12 (n=189) | 543.9 ± 144.34 |
| Week 24 (n=181) | 536.3 ± 144.32 |
| Week 38 (n=171) | 557.8 ± 144.23 |
| Week 52 (n=168) | 539.4 ± 147.04 |
| Early Withdrawal (up to Week 52) (n=32) | 329.1 ± 257.30 |
| Follow-up Visit 2 (Week 76) (n=18) | 523.4 ± 161.14 |
Collected over Day 1 up to approximately 95 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab | — | 17/227 (7.5%) | 36/227 (15.9%) |
| Event | Tocilizumab |
|---|---|
| Stress cardiomyopathyCardiac disorders | 1/227 |
| PneumoniaInfections and infestations | 1/227 |
| Skin infectionInfections and infestations | 1/227 |
| Humerus fractureInjury, poisoning and procedural complications | 1/227 |
| Wrist fractureInjury, poisoning and procedural complications | 1/227 |
| Carcinoembryonic antigen increasedInvestigations | 1/227 |
| Hepatic enzyme increasedInvestigations | 1/227 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/227 |
| Ovarian cystReproductive system and breast disorders | 1/227 |
| PleurisyRespiratory, thoracic and mediastinal disorders | 1/227 |
| Event | Tocilizumab |
|---|---|
| InfluenzaInfections and infestations | 23/227 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/227 |
| Transaminases increasedInvestigations | 15/227 |
| BronchitisInfections and infestations | 15/227 |
| Urinary tract infectionInfections and infestations | 12/227 |
Full Analysis Set (FAS) included all recruited participants who received at least one dose of SC tocilizumab.
| Age, Continuous(years) | Tocilizumab |
|---|---|
| Mean | 54.7 ± 12.12 |
| Sex: Female, Male(Participants) | Tocilizumab |
|---|---|
| Female | 197 |
| Male | 30 |
Ran from Sep 2013 to primary completion in Sep 2015, 24 months.
Results were first posted in Dec 2016, 1 year 3 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 24 months is close to that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab